BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,067 filers reported holding BAXTER INTL INC in Q2 2018. The put-call ratio across all filers is 0.99 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $91,410,884 | +10.1% | 2,422,122 | +32.9% | 0.62% | +0.5% |
| Q2 2023 | $83,015,878 | +39.0% | 1,822,122 | +23.8% | 0.62% | +18.2% |
| Q1 2023 | $59,709,268 | +28.7% | 1,472,122 | +61.8% | 0.52% | +9.0% |
| Q4 2022 | $46,382,700 | +34.9% | 910,000 | +127.9% | 0.48% | -7.9% |
| Q2 2020 | $34,373,000 | -41.1% | 399,221 | -44.4% | 0.52% | -55.1% |
| Q1 2020 | $58,340,000 | +24.6% | 718,561 | +28.3% | 1.16% | +88.2% |
| Q4 2019 | $46,822,000 | +50.9% | 559,938 | +33.2% | 0.62% | +121.9% |
| Q2 2018 | $31,029,000 | +7.4% | 420,217 | -5.4% | 0.28% | +16.3% |
| Q1 2018 | $28,899,000 | -55.3% | 444,323 | -55.6% | 0.24% | -53.5% |
| Q4 2017 | $64,698,000 | -26.4% | 1,000,901 | -45.8% | 0.51% | -36.8% |
| Q3 2016 | $87,889,000 | -20.7% | 1,846,415 | -24.6% | 0.81% | -21.9% |
| Q2 2016 | $110,790,000 | +15.1% | 2,450,018 | +77.9% | 1.04% | +86.2% |
| Q2 2015 | $96,282,000 | -24.9% | 1,376,836 | -22.4% | 0.56% | -80.4% |
| Q2 2014 | $128,209,000 | +7.4% | 1,773,300 | +9.3% | 2.85% | -13.1% |
| Q1 2014 | $119,384,000 | – | 1,622,500 | – | 3.28% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |